Werewolf Therapeutics, Inc.HOWLNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank40
3Y CAGR-32.1%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-32.1%/yr
Annual compound
Percentile
P40
Within normal range
vs 3Y Ago
0.3x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2024 | 35.09% |
| 2023 | -22.29% |
| 2022 | 52.43% |
| 2021 | 111.94% |
| 2020 | 162.48% |
| 2019 | 0.00% |